Lamb Healthcare Center
Lamb Healthcare Center was paid $433K by Medicaid between Nov 2020 and Nov 2024, across 25 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 39% of everything it billed.
LITTLEFIELD, TX 79339
Next to other General Acute Care Hospital providers in Texas
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Paid by month
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 280 | $14K | |
| 2021 | 3,590 | $140K | |
| 2022 | 6,027 | $159K | |
| 2023 | 3,820 | $102K | |
| 2024incomplete | 1,134 | $16K |
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 39% | 2,014 | 1,887 | $167K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 22% | 682 | 652 | $95K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 14% | 2,608 | 2,447 | $62K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 6.7% | 662 | 633 | $29K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 3.9% | 61 | 56 | $17K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 3.3% | 415 | 391 | $14K |
| S8301 | Infection control supplies, not otherwise specified | 3.2% | 2,762 | 2,578 | $14K |
| 80053 | Comprehensive metabolic panel | 2.1% | 1,205 | 1,087 | $9K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.3% | 1,163 | 1,048 | $6K |
| 84445 | 1.3% | 132 | 121 | $6K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 299 | 275 | $3K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 277 | 203 | $2K |
13 more codes
| 36415 | Collection of venous blood by venipuncture | <1% | 1,792 | $2K |
| 87070 | <1% | 174 | $2K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 148 | $1K |
| 99072 | <1% | 64 | $632.92 | |
| 99070 | <1% | 60 | $550.97 | |
| 86780 | <1% | 26 | $539.06 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 13 | $527.34 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 59 | $463.62 |
| 86703 | <1% | 25 | $437.33 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 119 | $269.83 |
| 80061 | Lipid panel | <1% | 49 | $152.17 |
| 81001 | <1% | 28 | $8.46 | |
| 87400 | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.